<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is characterized by <z:hpo ids='HP_0004419'>recurrent thrombosis</z:hpo> and pregnancy morbidity in association with the persistent presence of circulating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) </plain></SENT>
<SENT sid="1" pm="."><plain>APS remains the most frequent cause of acquired <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo> and <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriage</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Long-term anticoagulation therapy is the only treatment with proven benefit in the APS </plain></SENT>
<SENT sid="3" pm="."><plain>Anticoagulation is not effective in <z:hpo ids='HP_0000001'>all</z:hpo> patients and carries a risk of <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Recent improvements in the understanding of the pathogenic mechanisms have led to the identification of potential targets and future therapies for APS </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast to non-specific anticoagulation, the emergence of immunomodulatory drugs provides the possibility of interfering with specific pathogenic pathways </plain></SENT>
<SENT sid="6" pm="."><plain>Novel therapies might be used in the future for APS </plain></SENT>
</text></document>